Northwest Biotherapeutics' DCVax for tumors shows positive Phase I/II results Northwest Biotherapeutics announced that, in the ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors, all 9 out of 9 patients who have received 4 of the 6 planned injections are showing tumor cell death, tumor shrinkage, substantial immune cell accumulation in their tumors and/or stabilization of their advanced cancer. In addition, in 3 of these 9 patients, biopsies now show no live tumor cells in the injected tumor. The company plans to report more details when the patients are further along in the treatment regimen.
Northwest Biotherapeutics files to delay Form 10-K The company requires additional time to complete its year end procedures. Those procedures could not be completed without incurring undue hardship and expense. The company undertakes the responsibility to file such annual report no later than fifteen days after its original date.